Study details
Enrolling now
Smoking Cessation With Varenicline in Schizophrenia
Corporal Michael J. Crescenz VA Medical Center
NCT IDNCT03495024ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
10
Study length
about 1.5 years
Ages
18–75
Locations
1 site in PA
About this study
Researchers are testing if stopping smoking with varenicline helps reduce neurological side effects from antipsychotic medications. The trial will involve 10 people with schizophrenia who are smokers and have a condition called tardive dyskinesia while taking antipsychotics. Researchers will monitor changes in smoking status and neurological symptoms over 546 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Varenicline
PhasePhase 4
DrugVarenicline
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low12%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
varenicline
Drug routes
oral (Oral Tablet)
Body systems
Psychiatry / Mental Health